Printer Friendly

INNOVET BIOTECH PRODUCT MEETS USDA PERFORMANCE STANDARDS FOR LICENSING

 WEST PALM BEACH, Fla., Dec. 1 /PRNewswire/ -- InnoVet, Inc. (AMEX: IVT.EC) announced today it has received confirmation from the U.S. Department of Agriculture (USDA) that the USDA has accepted the safety and efficacy data submitted to support use of IVET-629 in treating chronic respiratory disease in horses.
 InnoVet said it expects to begin marketing the product early in 1994.
 InnoVet President and CEO Dr. Jesse W. Houdeshell said IVET-629 is the first product from the company's research efforts and will be good news for the equine industry. "Chronic respiratory disease costs horse owners over $300 million each year," Houdeshell said. "For example, considering just show and race horses, over 800,000 animals are exposed to potential infection each year as they are moved from one location to another."
 Houdeshell said studies have shown IVET-629 works within a few hours of injection, and improvement in the animal's health is noticeable within 72 hours. "In clinical trials, our product has shown clear benefits over using just antibiotics," he said.
 IVET-629 is a patented (U.S. Patent number 5219578) biological product which stimulates the animal's immune system. A major university study indicates IVET-629 stimulates the activity of B-lymphocytes, the body's first line of defense against infection, as well as macrophage and natural killer cells. InnoVet had submitted the Product License Application for use of IVET-629 in horses to the USDA earlier this year.
 Houdeshell said the product has shown promise in other studies as well. "Based on clinical trials, we are developing IVET-629 for treatment of shipping fever in cattle," he said. "The benefits could be substantial, since it's estimated that this disease syndrome costs the cattle industry $3 billion a year."
 "In addition, a study at the Ohio State University indicated IVET-629 has activity in treating solid tumors," Houdeshell said. "We have studies under way to evaluate the potential of IVET-629 to fight cancer in dogs and cats."
 The company said it plans to submit additional Product License Applications to the USDA for use of IVET-629 in cattle, dogs and cats.
 InnoVet, Inc., headquartered in West Palm Beach, is dedicated to the research, development and marketing of innovative pharmaceutical, biological, diagnostic and nutritional products to address the needs of the animal health and agriculture markets.
 -0- 12/1/93
 /CONTACT: Dr. Jesse W. Houdeshell, president and CEO of InnoVet, 407-687-8088, or David Crosson of INFOCUS, 609-683-9055, for InnoVet/
 (IVT)


CO: InnoVet, Inc. ST: Florida IN: MTC SU: LIC

MP-MK -- PH001 -- 9077 12/01/93 08:55 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 1, 1993
Words:417
Previous Article:CALIFORNIA ENERGY TERMINATES ACQUISITION OF WESTMORELAND ENERGY COMPANY
Next Article:PROCYTE LICENSES WOUND HEALING TECHNOLOGY TO PARTNER IN JAPAN
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters